O. Sitbon, Maurice Beghetti, Jérôme Petit
Sep 1, 2006
Citations
1
Influential Citations
52
Citations
Journal
European Journal of Clinical Investigation
Abstract
Background Bosentan is an effective first‐line therapy in New York Heart Association (NYHA) III patients with idiopathic pulmonary arterial hypertension (PAH). Pre‐clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD).